ADVANCED ENZYME TECHNOLOGIES Financial Statement Analysis
|
||
|
The Revenues of ADVANCED ENZYME TECHNOLOGIES have increased by 2.13% YoY .
The Earnings Per Share (EPS) of ADVANCED ENZYME TECHNOLOGIES has decreased by -11.68 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
ADVANCED ENZYME TECHNOLOGIES Last 5 Annual Financial Results
[BOM: 540025|NSE : ADVENZYMES]
| Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
|---|---|---|---|---|---|
| Revenues | ₹541 Cr | ₹529 Cr | ₹502 Cr | ₹444 Cr | ₹420 Cr |
| Expenses | ₹383 Cr | ₹327 Cr | ₹269 Cr | ₹241 Cr | ₹237 Cr |
| Operating Profit (Excl OI) | ₹157 Cr | ₹203 Cr | ₹233 Cr | ₹203 Cr | ₹183 Cr |
| Other Income | ₹25 Cr | ₹6.42 Cr | ₹8.85 Cr | ₹5.88 Cr | ₹5.72 Cr |
| Interest | ₹3.48 Cr | ₹2.96 Cr | ₹2.57 Cr | ₹4.08 Cr | ₹5.20 Cr |
| Depreciation | ₹35 Cr | ₹35 Cr | ₹29 Cr | ₹26 Cr | ₹21 Cr |
| Profit Before Tax | ₹140 Cr | ₹171 Cr | ₹210 Cr | ₹179 Cr | ₹162 Cr |
| Profit After Tax | ₹104 Cr | ₹124 Cr | ₹151 Cr | ₹133 Cr | ₹116 Cr |
| Consolidated Net Profit | ₹106 Cr | ₹120 Cr | ₹146 Cr | ₹129 Cr | ₹111 Cr |
| Earnings Per Share (Rs) | ₹9.45 | ₹10.70 | ₹13.06 | ₹11.58 | ₹9.95 |
| PAT Margin (%) | 19.18 | 23.34 | 29.88 | 29.96 | 27.62 |
| ROE(%) | 8.94 | 12.04 | 16.77 | 17.61 | 18.82 |
| ROCE(%) | 12.26 | 16.66 | 22.93 | 23.21 | 24.96 |
| Total Debt/Equity(x) | 0.01 | 0.01 | 0.02 | 0.03 | 0.05 |
Key Financials |
||
| Market Cap | : | ₹ 4,406.6 Cr |
| Revenue (TTM) | : | ₹ 604.8 Cr |
| Net Profit(TTM) | : | ₹ 139.2 Cr |
| EPS (TTM) | : | ₹ 12.5 |
| P/E (TTM) | : | 31.7 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| ADVANCED ENZYME TECHNOLOGIES | 0.7% | 9.1% | 52.9% |
| SUN PHARMACEUTICAL INDUSTRIES | 0.3% | -7.5% | 53.9% |
| CIPLA | 1.1% | -4.8% | 56.4% |
| DR REDDYS LABORATORIES | 1.6% | 1.6% | 27.6% |
| ZYDUS LIFESCIENCES | 5.2% | -0.2% | 90.1% |
| DIVIS LABORATORIES | -1.9% | 10.7% | 21.4% |
| MANKIND PHARMA | -2.3% | 0.1% | NA |
| TORRENT PHARMACEUTICALS | 1.6% | 2% | 61.8% |
| LUPIN | 2.4% | 2% | 132.5% |
ADVANCED ENZYME TECHNOLOGIES Revenues
[BOM: 540025|NSE : ADVENZYMES]
| Y-o-Y | 2.13 % |
| 5 Yr CAGR | 6.54 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹541 Cr | 2.13 | |
| Mar2022 | ₹529 Cr | 5.49 | |
| Mar2021 | ₹502 Cr | 13.03 | |
| Mar2020 | ₹444 Cr | 5.81 | |
| Mar2019 | ₹420 Cr | - | |
ADVANCED ENZYME TECHNOLOGIES Operating Profit
[BOM: 540025|NSE : ADVENZYMES]
| Y-o-Y | -22.25 % |
| 5 Yr CAGR | -3.62 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹157 Cr | -22.25 | |
| Mar2022 | ₹203 Cr | -12.90 | |
| Mar2021 | ₹233 Cr | 14.49 | |
| Mar2020 | ₹203 Cr | 11.27 | |
| Mar2019 | ₹183 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -23.88 % |
| 5 Yr CAGR | -9.54 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | 29.13% | -23.88 | |
| Mar2022 | 38.27% | -17.41 | |
| Mar2021 | 46.34% | 1.29 | |
| Mar2020 | 45.75% | 5.15 | |
| Mar2019 | 43.51% | - | |
ADVANCED ENZYME TECHNOLOGIES Profit After Tax
[BOM: 540025|NSE : ADVENZYMES]
| Y-o-Y | -11.66 % |
| 5 Yr CAGR | -1.24 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹106 Cr | -11.66 | |
| Mar2022 | ₹120 Cr | -18.06 | |
| Mar2021 | ₹146 Cr | 12.87 | |
| Mar2020 | ₹129 Cr | 16.42 | |
| Mar2019 | ₹111 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -17.82 % |
| 5 Yr CAGR | -8.71 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | 19.18 % | -17.82 | |
| Mar2022 | 23.34 % | -21.89 | |
| Mar2021 | 29.88 % | -0.27 | |
| Mar2020 | 29.96 % | 8.47 | |
| Mar2019 | 27.62 % | - | |
ADVANCED ENZYME TECHNOLOGIES Earnings Per Share (EPS)
[BOM: 540025|NSE : ADVENZYMES]
| Y-o-Y | -11.68 % |
| 5 Yr CAGR | -1.28 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹9.45 | -11.68 | |
| Mar2022 | ₹11 | -18.07 | |
| Mar2021 | ₹13 | 12.78 | |
| Mar2020 | ₹12 | 16.38 | |
| Mar2019 | ₹9.95 | - | |
ADVANCED ENZYME TECHNOLOGIES Return on Capital Employed (ROCE)
[BOM: 540025|NSE : ADVENZYMES]
| Y-o-Y | -26.41 % |
| 5 Yr CAGR | -16.28 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | 12.26% | -26.41 | |
| Mar2022 | 16.66% | -27.34 | |
| Mar2021 | 22.93% | -1.21 | |
| Mar2020 | 23.21% | -7.01 | |
| Mar2019 | 24.96% | - | |
ADVANCED ENZYME TECHNOLOGIES Share Price vs Sensex
| Current Share Price | : | ₹394.2 |
| Current MarketCap | : | ₹ 4,406.6 Cr |
| Updated EOD on | : | May 03,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ADVANCED ENZYME TECHNOLOGIES | 0.7% |
9.1% |
52.9% |
| SENSEX | -0.6% |
0.3% |
21.8% |
ADVANCED ENZYME TECHNOLOGIES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE MIDSMALLCAP | 1.4% | 8.6% | 66.5% |
| S&P BSE HEALTHCARE | 0.8% | 1.5% | 55.8% |
| S&P BSE ALLCAP | 0.4% | 3.7% | 40% |
| S&P BSE SMALL CAP | 0.2% | 9.3% | 64.7% |
No NSE index found
You may also like the below Video Courses
FAQ about ADVANCED ENZYME TECHNOLOGIES Financials
How the annual revenues of ADVANCED ENZYME TECHNOLOGIES have changed ?
The Revenues of ADVANCED ENZYME TECHNOLOGIES have increased by 2.13% YoY .
How the Earnings per Share (EPS) of ADVANCED ENZYME TECHNOLOGIES have changed?
The Earnings Per Share (EPS) of ADVANCED ENZYME TECHNOLOGIES has decreased by -11.68 % YoY .
Check out Intrinsic Value of Peers of ADVANCED ENZYME TECHNOLOGIES
Compare Stock Analytics of Peers of ADVANCED ENZYME TECHNOLOGIES
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
